CA3168980A1 - Compositions and methods for treating cancer and tumor - Google Patents

Compositions and methods for treating cancer and tumor Download PDF

Info

Publication number
CA3168980A1
CA3168980A1 CA3168980A CA3168980A CA3168980A1 CA 3168980 A1 CA3168980 A1 CA 3168980A1 CA 3168980 A CA3168980 A CA 3168980A CA 3168980 A CA3168980 A CA 3168980A CA 3168980 A1 CA3168980 A1 CA 3168980A1
Authority
CA
Canada
Prior art keywords
day
body weight
tumor
cancer
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3168980A
Other languages
English (en)
French (fr)
Inventor
Sin Wook Kang
Kyeongsoon KIM
Ji Hye SUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oblato Inc
Original Assignee
Oblato Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblato Inc filed Critical Oblato Inc
Publication of CA3168980A1 publication Critical patent/CA3168980A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3168980A 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor Pending CA3168980A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062980645P 2020-02-24 2020-02-24
US62/980,645 2020-02-24
PCT/US2021/019457 WO2021173702A1 (en) 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor

Publications (1)

Publication Number Publication Date
CA3168980A1 true CA3168980A1 (en) 2021-09-02

Family

ID=77490220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3168980A Pending CA3168980A1 (en) 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor

Country Status (8)

Country Link
US (1) US20230092005A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110315A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023514742A (cg-RX-API-DMAC7.html)
KR (1) KR20220145861A (cg-RX-API-DMAC7.html)
CN (1) CN115151250A (cg-RX-API-DMAC7.html)
AU (1) AU2021228654A1 (cg-RX-API-DMAC7.html)
CA (1) CA3168980A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021173702A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
AU2009214727B2 (en) * 2008-02-12 2014-12-11 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
CA2735859C (en) * 2008-09-02 2016-08-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl tert-butyl nitrone for the treatment of gliomas
EP2670425A4 (en) * 2011-01-31 2015-07-01 Oklahoma Med Res Found UBIQUITIN-INTERACTIVE MOTIVE PEPTIDES AS CANCER THERAPEUTICS
EP3570826A4 (en) * 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
KR101905864B1 (ko) * 2017-03-20 2018-10-08 아주대학교산학협력단 Sulf2 유전자를 이용한 소라페닙 치료에 대한 감수성 예측방법 및 sulf2 저해제를 포함하는 암 치료용 조성물
CN111132672A (zh) * 2017-09-20 2020-05-08 俄克拉荷马医学研究基金会 抗药性胶质瘤的治疗
WO2019213245A1 (en) * 2018-05-03 2019-11-07 Hough Ear Institute Methods for reducing accumulated pathologic tau protein

Also Published As

Publication number Publication date
WO2021173702A8 (en) 2022-08-18
EP4110315A4 (en) 2024-03-06
CN115151250A (zh) 2022-10-04
AU2021228654A1 (en) 2022-10-13
WO2021173702A1 (en) 2021-09-02
EP4110315A1 (en) 2023-01-04
US20230092005A1 (en) 2023-03-23
KR20220145861A (ko) 2022-10-31
JP2023514742A (ja) 2023-04-07

Similar Documents

Publication Publication Date Title
US20230093147A1 (en) Methods and compositions relating to improved combination therapies
US20240350439A1 (en) Calcium lactate compositions and methods of use
JP2020505433A (ja) Hsp90阻害剤を使用してがんを治療するための方法
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
JP2019147812A (ja) 神経膠芽腫の治療のための併用療法
JP7579636B2 (ja) 膵がん治療のための組み合わせ治療薬
US10905661B2 (en) Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
KR20230005185A (ko) 할로겐화 잔텐의 경구 투여에 의한 고형 암성 종양의 치료
US20240099999A1 (en) Use of colchicine to inhibit tumor growth and metastases
TW202404571A (zh) 藥物組成物及化療劑用於製備治療癌症之藥物的用途
JP2022160654A (ja) 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ
CN118139642A (zh) 治疗癌症的组合物和方法
US20230092005A1 (en) Compositions and methods for treating cancer and tumor
US11484591B2 (en) Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
US12064507B2 (en) Composition and method for oral treatment of leukemia
US20230058726A1 (en) Chemoprevention using controlled- release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
JP7525638B2 (ja) 白血病の経口処置のための組成物及び方法
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
US20210113692A1 (en) Dosing regimen
HK40118808A (en) All-trans retinoic acid liposomes and their application to tumor therapy
HK40105345A (en) Compositions and methods for treatment of cancer
EA045002B1 (ru) Применение колхицина для ингибирования роста опухоли и метастазов

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250826

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20260402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703